The Dementia Consortium supports collaborative target validation and drug discovery projects from academia and SMEs. They offer a unique collaborative model bringing together the charity and industry sectors to help accelerate development of therapies for novel dementia targets.
What do they offer?
The Dementia Consortium provides drug discovery resources, project management, industry expertise and tools as well as full funding support for projects. They can support small molecule or antibody-based strategies and aim to generate tools to achieve preclinical target validation. Their ultimate goal is to progress successful projects from laboratories towards the clinic.
Applications Open
Applications to collaborate with the Dementia Consortium are open globally to academic researchers and SMEs. Applications are reviewed six times per year. Please register your details to download the application form now.
What they are looking for:
Projects focused on novel molecular targets in any neurodegenerative disease (including Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, tauopathies, vascular dementia, Amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntingdon’s disease)
Evidence linking the target to human disease and confidence that target modulation would have a therapeutic effect
Collaborators with strong biology expertise and access to enabling assays, reagents and disease models
The application form NEXT DEADLINE: 12 September 2017 and 14 November 2017
